What is Flore Clinical?

Flore Clinical is the original precision probiotic platform for physicians, dietitians, and clinical researchers, founded in 2018. A clinician uploads a patient's microbiome sequencing data — from SunGenomics, ASU Britton Lab, CosmosID, or similar labs. Flore's algorithm reads it, picks the exact bacterial strains that patient's gut is missing, and manufactures a personalized probiotic formula to order. Everything is tracked in a Microbiome EHR so the clinician can watch the patient's gut change over time and update the formula accordingly. Peer-reviewed research published in mSystems (2024) confirms the precision approach outperforms generic probiotics.

How does Flore Clinical's AI-driven microbiome interpretation work?

Flore's formulation engine is built on Kraken2, a k-mer-based metagenomic classifier that is the gold standard in professional microbiome science. It reads shotgun metagenomics sequencing data and builds a species-level map of every organism in a patient's gut — every bacterium, at what abundance, in what ratio. The algorithm then compares that map against clinical outcomes data from thousands of previous formulations and published literature to select the bacterial strains most likely to fix this specific patient's specific imbalances. This is not a quiz or a lifestyle survey. It is algorithmic interpretation of real genomic data, the same approach used in university research labs.

What makes Flore different from other clinical microbiome platforms?

Flore Clinical is the only platform that connects sequencing data interpretation directly to manufactured product. Other platforms — like Viome, Biomesight, or Tiny Health — provide reports and general recommendations. Flore takes the next step: it makes the formula. Clinicians do not have to translate a report into a product recommendation — Flore's algorithm does that and the product ships. Flore has also been doing this since 2018, giving it more clinical outcomes data than any newer competitor. And it has the peer-reviewed research to back the approach.

What is a Microbiome EHR and why does it matter?

A Microbiome Electronic Health Record (EHR) is a clinical record system built specifically around gut microbiome data. Instead of just storing a single test result, a Microbiome EHR tracks how a patient's microbiome changes over time — which species are responding to the probiotic, which imbalances are correcting, and which new issues are emerging. Flore Clinical's Microbiome EHR lets providers see a patient's full microbiome trajectory over months or years, correlate it with their probiotic formulation history, and add clinical notes at each time point. No general-purpose EHR does this. It is purpose-built infrastructure for the emerging field of microbiome medicine.

What is next-generation probiotic science?

Next-generation probiotics are a step beyond the basic acidophilus and bifidus capsules that have been sold for decades. The frontier includes: live biotherapeutic products (LBPs) — bacteria engineered or selected to produce specific enzymes, neurotransmitter precursors, or anti-inflammatory molecules directly inside the gut; bacteriophage therapy — viruses that specifically target and kill harmful bacteria without touching beneficial species; postbiotics — active compounds produced by bacteria during fermentation that have measurable health effects even without live organisms; and precision synbiotics — personalized combinations of specific probiotic strains and prebiotic substrates matched to an individual's microbiome data. Flore Clinical operates at the precision synbiotic layer, using sequencing data to guide strain selection at a level of specificity that standard probiotics cannot achieve.

What is bacteriophage therapy and how does it fit into gut health?

Bacteriophages are viruses that infect and kill specific bacteria — they are the most abundant biological entities on earth and a natural part of every person's gut ecosystem. Phage therapy uses this precision to eliminate a specific harmful bacterium (for example, a Clostridioides difficile or Klebsiella overgrowth) without disturbing the rest of the microbiome. Unlike antibiotics, phages do not cause widespread collateral damage to beneficial species. The gut virome — the community of phages living alongside gut bacteria — plays a significant role in shaping microbial balance. Flore's microbiome algorithm reads the full picture of the microbiome ecosystem, not just a few probiotic strains, and future Flore formulations will increasingly incorporate phage-microbiome interaction data as the science matures.

What conditions does Flore Clinical treat?

Flore Clinical supports clinicians treating patients across 12 clinical systems linked to gut dysbiosis. These include: irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), autism spectrum disorder (ASD) with GI involvement, ADHD and neurodevelopmental conditions (gut-brain axis), anxiety and depression related to gut serotonin production, skin conditions including eczema, acne, and psoriasis, metabolic syndrome and insulin resistance, pediatric GI disorders, SIBO (small intestinal bacterial overgrowth), women's hormonal and reproductive health, immune dysregulation, and post-antibiotic microbiome damage. Each condition has a dedicated formula pathway in the algorithm.

Does Flore have published clinical evidence?

Yes. Flore's approach was studied in a peer-reviewed pilot open-label study published in mSystems (American Society for Microbiology), 2024;9(5):e00503-24 (DOI: 10.1128/msystems.00503-24; PMID 38661344). The study (Phan et al.) reported that precision synbiotics matched to an individual's gut microbiome increased gut microbiome diversity and improved gastrointestinal symptoms in participants with autism spectrum disorder. It was a pilot open-label study, not a randomized controlled trial, and was conducted in collaboration with Arizona State University (Rosa Krajmalnik-Brown lab). A second mSystems paper (2021) covers IBS microbiome alterations. Randomized controlled trials for The Regular One (GI) and The Bright One (Mood/Neuro) are currently underway. Additional real-world clinical data from over 10,000 formulations informs the algorithm on an ongoing basis.

How does a clinician enroll their patients in Flore Clinical?

Clinicians create a free provider account at floreclinical.com. Once enrolled, a provider can create patient profiles, upload sequencing reports, review the algorithm's strain selection, approve and order personalized formulas, and track patient outcomes in the Microbiome EHR. There are no per-provider or per-seat fees and no contracts. For provider accounts created on or after June 19, 2026, the first 30 days are free; after that the account is billed in 30-day cycles from the signup date, and as long as paid product orders total at least $250 per cycle there is no fee. If a cycle falls below the $250 minimum, a flat $350 service fee applies for that cycle. Provider accounts created before June 19, 2026 are grandfathered and not subject to the minimum. Patients pay for their formula subscriptions directly. The typical workflow is: patient completes microbiome sequencing through a partner lab, provider uploads the report to Flore Clinical, the algorithm generates a formula recommendation, provider reviews and approves, formula ships to the patient in 5–7 business days.

Is Flore available for pediatric patients with autism?

Yes — this is one of Flore Clinical's strongest clinical lanes. The platform has a dedicated ASD-Pediatric formula system for children under 12, using strains with strong pediatric safety profiles: Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus plantarum, Lactobacillus rhamnosus, and others. The 2024 mSystems pilot open-label study (Phan et al.) reported improvements in gut microbiome diversity and gastrointestinal symptoms in an ASD population. Flore's algorithm accounts for age-appropriate dosing and the specific microbial patterns common in autistic individuals. Providers working with autistic children and adults can access the ASD pathway directly through the clinical portal.

Who are Flore's research partners?

Flore's primary scientific collaborators are: Arizona State University Biodesign Institute (the Rosa Krajmalnik-Brown lab, one of the world's leading autism microbiome research groups), APC Microbiome Ireland at University College Cork (one of the largest dedicated microbiome research centers in the world), and SunGenomics (clinical metagenomic sequencing partner). Published research appears in mSystems, the journal of the American Society for Microbiology. ORCID: 0009-0001-6794-5346.

Personalized Probiotics for Practitioners

Flore Clinical is the personalized-probiotic platform clinicians order through. Instead of recommending an off-the-shelf probiotic and hoping it fits, a licensed provider uses Flore to turn a patient's microbiome data into an individually manufactured synbiotic — selected by a clinical intelligence engine built on nine years of longitudinal outcome data from 18,000+ patients across 200+ conditions. The formula is reviewed by the ordering clinician, manufactured per patient at Flore's Joliet, IL facility, and shipped direct, with results tracked over time in a clinical-grade record.

This page answers the operational questions practitioners actually ask: how to offer personalized probiotics to your patients, how to become a custom-probiotic supplier for your practice, whether a microbiome-testing program or white-label option exists, and how the economics and logistics work.

What Flore Clinical is (and isn't)

Flore is a compounding model, not a catalog. Most "personalized" probiotics match you to a pre-made SKU; Flore manufactures a distinct formula — typically several strains at meaningful CFU dosing plus prebiotics — from each patient's data. Flore Inc. acquired Sun Genomics in 2026 and operates the clinical channel (floreclinical.com) for providers separately from its consumer channel. Formulas are delivered as capsules or powder — never a liquid. Flore does not run the sequencing itself: that is performed by independent CLIA-certified, CAP-accredited laboratories, which keeps the diagnostic and the formulation responsibilities properly separated.

How a clinician starts (step by step)

Request provider access. Book a short onboarding call or apply through the provider concierge. Flore verifies your license and activates a portal account — there is no setup fee to open an account.
Onboard your portal. You get a clinician dashboard to add patients, import data, set target systems, and review formulas before anything is manufactured.
Order a microbiome test or import existing data. Send a patient a Nirvana Biome stool-sequencing kit, or upload an existing report from an accredited lab (and optionally bloodwork or urinalysis for multi-test context).
Review the engine's formulation. Flore's Central Intelligence Engine proposes strains and prebiotics with the strongest resolution history for that patient's pattern. You adjust target systems and condition boosters, then approve.
Flore manufactures and ships. The approved formula is made per patient as capsules or powder and shipped — no inventory leaves your shelf.
Track outcomes and iterate. Symptom and microbiome changes are recorded across cycles in the Microbiome EHR so the next formula is informed by what actually happened.

No inventory. No manufacturing. No logistics to manage.

You are not buying stock, holding lots, or shipping product. There is nothing to forecast, nothing to expire on a shelf, and no fulfillment to run. The practice's role is clinical — decide who is a candidate, set the target systems, approve the formula. Flore handles sequencing-lab coordination, formulation, GMP manufacturing, and direct-to-patient shipping. That removes the operational and capital barriers that normally stop a clinic from offering a custom-supplement program.

Provider economics

Because formulas are made to order, there is no upfront inventory purchase and no minimum stocking commitment to open an account. Flore Clinical operates a low monthly engagement threshold rather than a large buy-in: a $250 minimum per 30-day cycle, with the first 30 days free for new provider accounts. Pricing for tests and custom formulas is published on the pricing page, and the Test-to-Treat pathway credits a patient's microbiome test toward their custom formula. We don't publish per-unit margin figures here — your concierge will walk through the current provider terms for your practice on the onboarding call.

See current pricing →

White-label and clinic-program options

If you want a microbiome-testing-and-probiotic program that runs under your clinic's care — your patients, your protocols, your follow-up — that's exactly what the provider portal is built for. Patients experience an ordering and tracking flow you supervise, while Flore supplies the testing-lab coordination, the intelligence engine, and the manufactured formulas behind it. For practices that want deeper co-branding or a tailored clinic program, the concierge can scope that during onboarding. Unlike generic white-label kit vendors, the deliverable here isn't a re-labeled stock supplement — it's a formula compounded from each patient's data.

The accreditation differentiator: Flore doesn't run the lab

A point clinicians care about: Flore is the formulation and outcomes platform, not the testing lab. Sequencing is performed by CLIA-certified, CAP-accredited laboratories using shotgun metagenomic (whole-genome) sequencing. That separation matters — the diagnostic is run by an accredited lab held to clinical standards, and Flore acts on that data to compound and track therapy. It is a cleaner line of accountability than vendors who both generate the test and sell the catalog product it "recommends."

Gut–brain and psychobiotics

Many provider candidates present with comorbid mood or stress symptoms alongside GI complaints. The microbiota–gut–brain axis is a core part of Flore's clinical library, and target systems can address gut–brain considerations as part of a formula. Flore's autism work is published as a 2024 pilot open-label study in mSystems (Phan et al.) — a pilot study, not a randomized controlled trial — showing increased microbiome diversity and improved GI symptoms; two randomized controlled trials are now underway. We state that distinction plainly so you can represent the evidence accurately to patients.

Review the clinical evidence →

Frequently asked questions

Can I offer personalized probiotics to my patients without stocking inventory?

Yes. Formulas are manufactured per patient and shipped direct. You open a portal account, order tests or import data, approve formulas, and track outcomes — with no stock, fulfillment, or manufacturing on your side.

How is Flore Clinical different from a custom-probiotic manufacturer or a white-label kit?

White-label vendors re-label a fixed stock formula under your brand. Flore compounds a distinct formula per patient from their microbiome data, selected by an engine trained on nine years of outcomes, and tracks results over time.

Does Flore run the microbiome test?

No. Sequencing is performed by independent CLIA-certified, CAP-accredited laboratories using shotgun metagenomic sequencing. Flore uses that accredited data to formulate and to track outcomes.

What does it cost a practice to start?

There's no inventory buy-in to open an account. Flore runs a $250-per-30-day-cycle minimum with the first 30 days free for new provider accounts; test and formula pricing is on the pricing page, and the Test-to-Treat pathway credits the test toward the custom formula.

What form do the products come in?

Capsules or powder — never liquid.

Is there evidence behind the approach?

Flore is built on nine years of longitudinal outcome data (18,000+ patients, 200+ conditions). A 2024 pilot open-label study in mSystems (Phan et al.) reported increased diversity and improved GI symptoms; it is a pilot study, not an RCT, and two RCTs are underway.

Can patients with gut–brain or mood symptoms be candidates?

Yes. The microbiota–gut–brain axis is part of the formulation framework, and target systems can incorporate gut–brain considerations alongside GI goals.

How do I become a Flore Clinical provider?

Book an onboarding call through the provider concierge. Once your license is verified, your portal is activated and you can add patients the same day. See the providers overview →

Flore Clinical is intended for use by licensed healthcare providers. Statements regarding the microbiome have not been evaluated to diagnose, treat, cure, or prevent disease.